Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Releases

  • Webcast Image Webcast
    Spring Bank/F-Star Business Combination  (Replay)
    Thursday, July 30, 2020 7:30 am EDT
Spring Bank Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Results
Announced agreement for strategic combination with F-star Therapeutics to advance a pipeline of multiple clinical-stage immuno-oncology programs Continued to advance IV SB 11285 clinical trial to additional monotherapy and combination dosing cohorts Abstracts for IV SB 11285 accepted by major
Spring Bank Pharmaceuticals and F-star Therapeutics Agree to Combine to Pursue Mission of Creating Next Generation Immunotherapies
Combined company will operate as F-star Therapeutics and advance pipeline of multiple clinical-stage immuno-oncology programs Combined company expected to have at least $40 million in cash prior to closing Spring Bank stockholders to receive two separate contingent value rights related to Spring
Spring Bank Advances IV SB 11285 Clinical Program
-      Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned monotherapy dose level and initiation of first co-administration dose level with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®) -    Clinical Poster for IV SB 11285 Phase 1a/1b
Spring Bank to Present at the Jefferies Virtual Global Healthcare Conference
HOPKINTON, Mass. , May 26, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will be
Spring Bank Announces Poster Presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
HOPKINTON, Mass. , May 20, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and inflammatory diseases, today announced that a trial in progress poster will be
Spring Bank Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results
Continues to advance IV SB 11285 clinical trial to additional dosing cohorts On track to include Roche’s Tecentriq ® in IV SB 11285 clinical trial in summer 2020 Advancing efforts to examine RIG-I and STING agonists portfolio as potential therapeutics and/or vaccine adjuvants for COVID-19
Spring Bank Provides Update on Business Operations & Clinical Program Progress During COVID-19 Pandemic
Pursuing collaborations to develop internal compounds for potential treatment of COVID-19 Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned dose level; initial patient dosed in next cohort Clinical abstracts for IV SB 11285 Phase 1a/1b trial
Spring Bank Announces Clinical Collaboration to Evaluate SB 11285 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors
HOPKINTON, Mass. , Feb. 25, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore
Spring Bank Pharmaceuticals Reports 2019 Fourth Quarter and Full-Year Financial Results
HOPKINTON, Mass. , Feb. 14, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and inflammatory diseases, today announced its financial results for the fourth
Spring Bank Discontinues Development of Inarigivir for the Treatment of HBV
Continuing to focus on immuno-oncology & inflammation, including IV STING agonist clinical program, oral STING antagonist platform and STING agonist ADCs Adjusting cost structure to fund operations into late 2022 HOPKINTON, Mass. , Jan. 29, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc.